Xenpozyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increased recognition of niemann-pick disease, advancements in recombinant protein production, expansion of orphan drug development programs, growing clinical trial activity in rare diseases, improved diagnostic testing availability.

The growth in the forecast period can be attributed to increasing investments in rare disease pipelines, growing use of personalized medicine approaches, expansion of newborn screening programs, rising global access to specialty biologics, continued innovation in enzyme stabilization technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare disease treatment development, expansion of recombinant enzyme manufacturing capabilities, rising emphasis on early diagnosis of lysosomal disorders, improved clinical management of asmd.

The growing prevalence of genetic disorders is expected to drive the growth of the xenpozyme market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, leading to various health complications. The rising prevalence is attributed to advances in genetic testing, greater awareness and diagnosis of rare diseases, and improvements in healthcare systems. Xenpozyme treats acid sphingomyelinase deficiency (ASMD), a genetic disorder, by providing the missing acid sphingomyelinase enzyme, which is essential for breaking down accumulated sphingomyelin. This therapy helps reduce harmful lipid buildup in cells, alleviates symptoms, and slows disease progression in ASMD patients. For example, according to the Cystic Fibrosis Trust, a UK-based charity supporting people with cystic fibrosis, in 2022 around 11,148 patients were registered, increasing to 11,318 in 2023 - a 1.5% year-over-year growth. Therefore, the rising prevalence of genetic disorders is expected to propel the growth of the xenpozyme market.

The expansion of healthcare infrastructure is also expected to support the growth of the xenpozyme market. Healthcare infrastructure includes the physical and organizational structures, facilities, resources, and systems required to deliver medical services to a population. Growth in infrastructure is driven by factors such as the aging population, increasing chronic disease prevalence, and technological advancements. Enhanced healthcare infrastructure supports xenpozyme by providing the necessary medical facilities, skilled healthcare professionals, diagnostic tools, and treatment protocols to enable effective drug administration, monitor patient progress, and manage potential side effects, ensuring optimal outcomes. For instance, according to the U.S. Centers for Medicare & Medicaid Services, in December 2024 healthcare expenditures in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion, or roughly $14,570 per individual. Therefore, the expansion of healthcare infrastructure drives the growth of the xenpozyme market.

The increasing demand for personalized medicine is expected to further propel the growth of the xenpozyme market. Personalized medicine is a healthcare approach that tailors treatments based on an individual’s genetic profile, lifestyle, and unique health needs to achieve better outcomes. Rising demand is driven by advancements in genetic research, improved understanding of individual health profiles, enhanced diagnostic tools, and the potential for more effective, targeted therapies. Xenpozyme delivers the missing enzyme to break down accumulated substances, providing treatment specifically tailored to address the mutation-driven enzyme deficiency in each patient, offering personalized care. For example, according to the Personalized Medicine Coalition, a U.S.-based healthcare organization, in 2023 the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is expected to drive the growth of the xenpozyme market.

Major companies operating in the xenpozyme market are Sanofi S.A.

North America was the largest region in the xenpozyme market in 2025. The regions covered in the xenpozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xenpozyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the xenpozyme market by increasing costs for imported bioprocessing equipment, recombinant production inputs, sterile filtration systems, and temperature-controlled logistics solutions. Europe and North America are particularly affected due to reliance on specialized imported biologics manufacturing infrastructure, while emerging markets face higher acquisition costs for advanced enzyme therapies. These tariffs are raising development and commercialization expenses and impacting market accessibility. At the same time, they are promoting regional biologics manufacturing capacity, encouraging technology transfer, and supporting long-term localization of enzyme replacement therapy production.

The xenpozyme market research report is one of a series of new reports that provides xenpozyme market statistics, including xenpozyme industry global market size, regional shares, competitors with a xenpozyme market share, detailed xenpozyme market segments, market trends and opportunities, and any further data you may need to thrive in the xenpozyme industry. This xenpozyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xenpozyme is an enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD), including Niemann-Pick disease types A, A/B, and B. It delivers recombinant human acid sphingomyelinase (rhASM) to replace the missing enzyme, allowing the breakdown of sphingomyelin, a lipid that accumulates in organs.

The primary indications for Xenpozyme are acid sphingomyelinase deficiency (ASMD) with Niemann-Pick disease type A and ASMD with Niemann-Pick disease type B. ASMD with Niemann-Pick disease type A affects patients who experience severe neurological and organ dysfunction due to a deficiency of acid sphingomyelinase. Xenpozyme is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various patient groups, including adults, elderly patients, and children.

The xenpozyme market consists of sales of reconstitution kits and accessories, administration devices, and complementary diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.